LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

Search

Iovance Biotherapeutics Inc

Closed

SectorHealthcare

2.26 -0.44

Overview

Share price change

24h

Current

Min

2.26

Max

2.32

Key metrics

By Trading Economics

Income

4.5M

-112M

Sales

11M

60M

Profit margin

-186.246

Employees

838

EBITDA

8.3M

-102M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+370.04% upside

Dividends

By Dow Jones

Next Earnings

6 Nov 2025

Market Stats

By TradingEconomics

Market Cap

-84M

861M

Previous open

2.7

Previous close

2.26

News Sentiment

By Acuity

50%

50%

183 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Iovance Biotherapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

15 Sept 2025, 22:39 UTC

Acquisitions, Mergers, Takeovers

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

15 Sept 2025, 16:43 UTC

Major Market Movers

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

15 Sept 2025, 16:42 UTC

Major Market Movers

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

15 Sept 2025, 16:35 UTC

Major Market Movers

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

15 Sept 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 Sept 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

15 Sept 2025, 23:34 UTC

Market Talk

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

15 Sept 2025, 22:48 UTC

Market Talk

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

15 Sept 2025, 22:12 UTC

Acquisitions, Mergers, Takeovers

CSL Expects Commercial Launch in 2029

15 Sept 2025, 22:12 UTC

Acquisitions, Mergers, Takeovers

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

15 Sept 2025, 22:11 UTC

Acquisitions, Mergers, Takeovers

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

15 Sept 2025, 22:11 UTC

Acquisitions, Mergers, Takeovers

CSL to Have Right to Exercise Option Based on Phase 3 Data

15 Sept 2025, 22:10 UTC

Acquisitions, Mergers, Takeovers

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

15 Sept 2025, 21:16 UTC

Acquisitions, Mergers, Takeovers

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

15 Sept 2025, 21:16 UTC

Acquisitions, Mergers, Takeovers

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

15 Sept 2025, 21:15 UTC

Acquisitions, Mergers, Takeovers

Chord Energy to Buy 48,000 Net Acres in the Williston Core

15 Sept 2025, 21:14 UTC

Acquisitions, Mergers, Takeovers

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

15 Sept 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 Sept 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15 Sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 Sept 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

15 Sept 2025, 19:14 UTC

Market Talk

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

15 Sept 2025, 18:16 UTC

Market Talk

Gold Powers to New High -- Market Talk

15 Sept 2025, 18:05 UTC

Market Talk

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

15 Sept 2025, 17:50 UTC

Acquisitions, Mergers, Takeovers

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

15 Sept 2025, 17:10 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 Sept 2025, 17:10 UTC

Market Talk

S&P Expects Fed, BOC to Cut Rates -- Market Talk

15 Sept 2025, 16:52 UTC

Market Talk

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

15 Sept 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

15 Sept 2025, 16:20 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

Peer Comparison

Price change

Iovance Biotherapeutics Inc Forecast

Price Target

By TipRanks

370.04% upside

12 Months Forecast

Average 10.67 USD  370.04%

High 20 USD

Low 1 USD

Based on 8 Wall Street analysts offering 12 month price targets forIovance Biotherapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

5

Buy

2

Hold

1

Sell

Technical Score

By Trading Central

3.0208 / 3.5Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

183 / 371 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
help-icon Live chat